Phase 3 RESPONSE-2 Study of Jakafi® (ruxolitinib) Meets Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
ASH Reveals Promising Datapoints for Incyte (INCY) - UBS
December 8, 2015 9:38 AM ESTUBS analyst, Matthew Roden, attended the ASH meeting and found several datapoints relevant to Incyte's (NASDAQ: INCY) Jakafi and competing JAK inhibitors. An exploratory analysis of the impact of anemia on Jakafi efficacy showed: patients with baseline anemia had a lower benefit than those without (expected);... More
